Serologic And Molecular Testing

The antiglobulin (Coombs) test

IgG antibodies and complement are too small to bridge the gap between red cells repelled by their negative surface charge (zeta potential), so they sensitize without visible agglutination. Antihuman globulin (AHG, Coombs reagent) is an antibody against human IgG and/or C3d that cross-links sensitized cells into a visible lattice. Two configurations exist and the MLS exam constantly contrasts them.

• Direct antiglobulin test (DAT): detects red cells already coated in vivo. The patient's washed cells go straight to AHG. A positive DAT points to autoimmune hemolytic anemia, hemolytic disease of the fetus and newborn, hemolytic transfusion reaction, or drug-induced antibodies. Polyspecific AHG positivity is followed by monospecific anti-IgG and anti-C3d to classify the coating (warm AIHA = IgG; cold agglutinin disease/PNH = C3d).
• Indirect antiglobulin test (IAT): detects sensitization performed in vitro during 37 C incubation. The IAT powers the antibody screen, antibody identification panel, antigen typing, and the antiglobulin crossmatch.

Reagents, controls, and enhancement

Check cells (IgG-coated control cells) are mandatory after a negative AHG reaction: if they fail to agglutinate, the AHG was neutralized, not active, and the negative result is invalid and must be repeated. This single rule appears on nearly every MLS practice form.

Proteolytic enzymes (ficin, papain) selectively remodel the membrane: they destroy Duffy (Fya/Fyb) and MNS (M, N, S) antigens while enhancing Rh, Kidd, Lewis, P1, and I reactivity. An antibody that reacts only with enzyme-treated cells, or vanishes after enzyme treatment, narrows identification fast.

False results and molecular testing

Causes of a false-positive DAT include heavy clotting in the sample, autoagglutinins, and overcentrifugation. False-negative AHG arises from inadequate cell washing (residual unbound globulin neutralizes AHG), delay before reading, or under-centrifugation — exactly why check cells exist.

Molecular testing complements serology when antigens cannot be reliably typed by reagents. RHD genotyping distinguishes weak D types: types 1, 2, and 3 can be managed as D-positive (the patient may receive D-positive red cells and does not need Rh immune globulin), whereas a serologic weak D of unknown type is conservatively managed as D-negative.

Genotyping also predicts a phenotype when a patient is recently transfused (donor cells create mixed-field serology that confounds typing), when reagents for a rare antigen are unavailable, when the DAT is positive and blocks typing, or when searching for antigen-negative units for a patient with multiple antibodies.

Resolving a forward/reverse ABO discrepancy serologically

Before reaching for molecular tools, the exam expects systematic serologic troubleshooting. A forward/reverse ABO discrepancy is approached by re-checking identification and repeating the test, then classifying the problem: extra reactions (acquired B, polyagglutination, rouleaux, cold autoantibody) versus missing reactions (subgroup A2 with anti-A1, hypogammaglobulinemia, newborn or elderly low isohemagglutinins). Rouleaux is resolved with a saline replacement, cold antibodies with prewarming, and subgroups with anti-A1 lectin (Dolichos biflorus).

Each maneuver has a specific control, and reporting an ABO group before resolving the discrepancy is a critical-error scenario.

Choosing and controlling the right test

The analytical decisions of this section are best summarized as a routine. First, define the clinical question — is the patient's own cell already coated (DAT), is there an antibody in the serum (IAT screen/panel), or does serology fail so genotype is needed? Second, choose the correct enhancement (LISS or PEG to speed uptake; enzymes to discriminate Duffy/MNS from Rh/Kidd). Third, validate every negative antiglobulin result with check cells and every positive DAT with monospecific reagents.

The applied skill the MLS exam rewards is matching test to question and proving the result with the correct control, not memorizing isolated definitions; practice items repeatedly hinge on whether you recognized that a missing check-cell reaction invalidates the run or that enzyme treatment explained a vanishing Duffy reaction.

Testing platforms and method comparison

Modern transfusion services use more than the classic tube method, and the exam may compare them. Tube testing grades agglutination from negative to 4+ and remains the reference for resolving discrepancies. Gel (column agglutination) traps agglutinates at the top of a microtube gel matrix during centrifugation, giving objective, stable, photographable results that improve standardization and are easy to read. Solid-phase red cell adherence captures reagent antigens on a microplate well; a positive antiglobulin reaction spreads cells across the well while a negative result forms a tight button.

Each platform still relies on the same antiglobulin principle and still requires controls. Knowing how a positive and negative result appears in gel versus solid phase, diffuse adherence or trapped band for positive, a clean button or pellet for negative, is a recurring method-recognition item that rewards visualizing the endpoint rather than memorizing a definition.